Chad M Cohen is Chief Financial Officer of Adaptive Biotechnologies Corp. Currently has a direct ownership of 21,604 shares of ADPT, which is worth approximately $119,254. The most recent transaction as insider was on Jun 08, 2021, when has been sold 10,000 shares (Common Stock) at a price of $6.55 per share, resulting in proceeds of $65,500. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 21.6K
0% 3M change
0% 12M change
Total Value Held $119,254

Chad M Cohen Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 08 2021
BUY
Exercise of conversion of derivative security
$65,500 $6.55 p/Share
10,000 Added 24.04%
31,604 Common Stock
May 12 2021
SELL
Open market or private sale
$326,300 $32.63 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
May 12 2021
BUY
Exercise of conversion of derivative security
$65,500 $6.55 p/Share
10,000 Added 24.04%
31,604 Common Stock
May 11 2021
SELL
Open market or private sale
$313,300 $31.33 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
May 11 2021
BUY
Exercise of conversion of derivative security
$65,500 $6.55 p/Share
10,000 Added 24.04%
31,604 Common Stock
Apr 07 2021
SELL
Open market or private sale
$419,700 $41.97 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Apr 07 2021
BUY
Exercise of conversion of derivative security
$63,200 $6.32 p/Share
10,000 Added 24.04%
31,604 Common Stock
Apr 06 2021
SELL
Open market or private sale
$409,500 $40.95 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Apr 06 2021
BUY
Exercise of conversion of derivative security
$63,200 $6.32 p/Share
10,000 Added 24.04%
31,604 Common Stock
Mar 10 2021
SELL
Open market or private sale
$425,400 $42.54 p/Share
10,000 Reduced 31.64%
21,604 Common Stock
Mar 10 2021
BUY
Exercise of conversion of derivative security
$63,200 $6.32 p/Share
10,000 Added 24.04%
31,604 Common Stock
Mar 09 2021
SELL
Open market or private sale
$404,100 $40.41 p/Share
10,000 Reduced 32.19%
21,064 Common Stock
Mar 09 2021
BUY
Exercise of conversion of derivative security
$63,200 $6.32 p/Share
10,000 Added 24.35%
31,064 Common Stock
Mar 04 2021
BUY
Grant, award, or other acquisition
-
20,604 Added 48.82%
21,604 Common Stock
Jan 29 2021
SELL
Open market or private sale
$2,836,000 $56.72 p/Share
50,000 Reduced 98.04%
1,000 Common Stock
Jan 29 2021
BUY
Exercise of conversion of derivative security
$316,000 $6.32 p/Share
50,000 Added 49.5%
51,000 Common Stock
Jan 28 2021
SELL
Open market or private sale
$2,800,500 $56.01 p/Share
50,000 Reduced 98.04%
1,000 Common Stock
Jan 28 2021
BUY
Exercise of conversion of derivative security
$316,000 $6.32 p/Share
50,000 Added 49.5%
51,000 Common Stock
Jan 26 2021
SELL
Open market or private sale
$3,204,500 $64.09 p/Share
50,000 Reduced 98.04%
1,000 Common Stock
Jan 26 2021
BUY
Exercise of conversion of derivative security
$316,000 $6.32 p/Share
50,000 Added 49.5%
51,000 Common Stock
Jan 25 2021
SELL
Open market or private sale
$3,318,500 $66.37 p/Share
50,000 Reduced 98.04%
1,000 Common Stock
Jan 25 2021
BUY
Exercise of conversion of derivative security
$316,000 $6.32 p/Share
50,000 Added 49.5%
51,000 Common Stock
Jan 20 2021
SELL
Open market or private sale
$3,375,000 $67.5 p/Share
50,000 Reduced 98.04%
1,000 Common Stock
Jan 20 2021
BUY
Exercise of conversion of derivative security
$316,000 $6.32 p/Share
50,000 Added 49.5%
51,000 Common Stock
Jan 19 2021
SELL
Open market or private sale
$3,441,000 $68.82 p/Share
50,000 Reduced 98.04%
1,000 Common Stock

Also insider at

VCSA
Vacasa, Inc. Technology
CMC

Chad M Cohen

Chief Financial Officer
Seattle, WA

Track Institutional and Insider Activities on ADPT

Follow Adaptive Biotechnologies Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT